Evidence map›Paper›PMID 40919256›Full record

ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

Pseudogenes in the carcinogenesis: epithelial-to-mesenchymal transition process and cancer initiating cells.

Tomasz Kolenda, Piotr Chałaj, Aleksandra Cichowicz, Aleksandra Trojańska, Andrzej Bałoniak, Malwina Kwaśniewska, Magda Odrobińska, Kacper Guglas, Joanna Kozłowska-Masłoń, Paulina Gieremek and 9 more

Abstract readReview
In one paragraph

Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tomasz Kolenda *Laboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Piotr Chałaj *Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Aleksandra Cichowicz *Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Aleksandra TrojańskaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Andrzej BałoniakDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Malwina KwaśniewskaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Magda OdrobińskaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Kacper GuglasLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Joanna Kozłowska-MasłońLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland.
Paulina GieremekDepartment of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Poznan, Poland.
Paulina PoterDepartment of Oncologic Pathology and Prophylaxis, Greater Poland Cancer Centre, Poznan, Poland.
Marlena Janiczek-PolewskaDepartment of Clinical Oncology, Greater Poland Cancer Centre, Poznan, Poland.
Anna Florczak-SubstykDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Anna PrzybyłaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Patrycja MantajRadiation Protection Department, Greater Poland Cancer Centre, Poznan, Poland.
Katarzyna RegulskaPharmacy, Greater Poland Cancer Centre, Poznan, Poland.
Beata Jadwiga StaniszDepartment of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Poznan, Poland.
Zefiryn CybulskiMicrobiology Laboratorium, Greater Poland Cancer Centre, Poznan, Poland.
Urszula KazimierczakDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Initially, pseudogenes were considered to be "junk DNA", and their biological role was unclear. However, some of the pseudogenes are engaged in the process of cancerogenesis and perform essential functions in competing for endogenous ribonucleic acid (ceRNA) networks and competing for RNA binding proteins (RBPs). They either positively or negatively regulate gene expression and act as suppressive and oncogenic transcripts. In this review, we look at some of the pseudogenes that play a role in the epithelial-to-mesenchymal transition (EMT) process and the maintenance of cancer-initiating cells (CIC), which are essential in understanding cancer development and progression metastasis and resistance to commonly used therapies. The group of discussed pseudogenes consists of

Indexed as

biomarkercancercancer-initiating cellsCICEMTepithelial-to-mesenchymal transitionnon-coding RNApseudogene

Identifiers

PMID40919256
PMCPMC12413218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.